1-7 of 7
Rodrigo Maegawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI)

Koji Sasaki, Michael Mauro, Moshe Yair Levy, Ehab L. Atallah, Paul B. Koller, Rodrigo Maegawa, Andrea Damon, Julie Kumar, Mahmudul Khan, Jorge E. Cortes
Journal: Blood
Blood (2022) 140 (Supplement 1): 6784–6786.
https://doi.org/10.1182/blood-2022-167044
Published: 2022
Journal Articles

Real-World Usage of Asciminib in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) in the United States (US) Using a Large Claims Database

Sudipto Mukherjee, Chi-Chang Chen, Magdaliz Gorritz, Islam Sadek, Serban Iorga, Zifan Zhou, Jing He, Rodrigo Maegawa, Andrea Damon, Germano Ferreira, Kejal Jadhav
Journal: Blood
Blood (2022) 140 (Supplement 1): 13297–13298.
https://doi.org/10.1182/blood-2022-166473
Published: 2022
Journal Articles

Clinical Characteristics and Late-Line Treatment Patterns of Patients with Chronic Myeloid Leukemia Who Received 2 Prior Lines of Tyrosine Kinase Inhibitor Therapy in US Community Oncology Practices

Pareshkumar Patel, Aditya Raju, Anna Coutinho, Rodrigo Maegawa, Orsolya Lunacsek, Kathryn Deyoung, Serban Iorga, Xiting Cao
Journal: Blood
Blood (2021) 138 (Supplement 1): 5036.
https://doi.org/10.1182/blood-2021-152619
Published: 2021
Journal Articles

Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

David Andorsky, Sarah Tomassetti, Yehuda E. Deutsch, E Randolph Broun, Ghayas C. Issa, Moshe Y. Levy, Michael W. Deininger, Rodrigo Maegawa, Alok Shrestha, Michael J. Mauro
Journal: Blood
Blood (2021) 138 (Supplement 1): 3599.
https://doi.org/10.1182/blood-2021-147337
Published: 2021
Journal Articles

Targeted Literature Review of Patient Reported Outcomes (PROs) in Chronic Myeloid Leukemia (CML) Patients Receiving Second and Later Lines of Treatment

Shiyu Zhang, Rodrigo Maegawa, MD, Savita Nandal, MBBS, MD, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140402
Published: 2020
Journal Articles

Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs Among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy

Ehab L. Atallah, MD, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Carmine Rossi, PhD, Annie Guerin, MSc, Pallavi Patwardhan, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-136074
Published: 2020
Journal Articles

Effectiveness of Second-Line (2L) Tyrosine Kinase Inhibitor (TKI) Therapy after Resistance or Intolerance to a Prior TKI in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP)

Sudipto Mukherjee, MD PhD MPH, Xiting Cao, Islam Sadek, Rodrigo Maegawa, MD, Dominick Latremouille-Viau, MSc, Irina Pivneva, Annie Guérin, B. Douglas Smith, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-137079
Published: 2020